You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Investigational Drug Information for RIST4721


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug RIST4721?

RIST4721 is an investigational drug.

There have been 6 clinical trials for RIST4721. The most recent clinical trial was a Phase 2 trial, which was initiated on July 30th 2022.

The most common disease conditions in clinical trials are Psoriasis, Blister, and Hereditary Autoinflammatory Diseases. The leading clinical trial sponsors are Aristea Therapeutics, Inc. and [disabled in preview].

There are four US patents protecting this investigational drug and one hundred and seventeen international patents.

Recent Clinical Trials for RIST4721
TitleSponsorPhase
A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)Aristea Therapeutics, Inc.Phase 2
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)Aristea Therapeutics, Inc.Phase 2
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)Aristea Therapeutics, Inc.Phase 2

See all RIST4721 clinical trials

Clinical Trial Summary for RIST4721

Top disease conditions for RIST4721
Top clinical trial sponsors for RIST4721

See all RIST4721 clinical trials

US Patents for RIST4721

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RIST4721 ⤷  Sign Up Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Sign Up
RIST4721 ⤷  Sign Up Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Sign Up
RIST4721 ⤷  Sign Up Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors AstraZeneca AB (Sodertalje, SE) ⤷  Sign Up
RIST4721 ⤷  Sign Up Certain (25)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RIST4721

Drugname Country Document Number Estimated Expiration Related US Patent
RIST4721 Argentina AR099177 2034-01-24 ⤷  Sign Up
RIST4721 Australia AU2015208932 2034-01-24 ⤷  Sign Up
RIST4721 Australia AU2017200338 2034-01-24 ⤷  Sign Up
RIST4721 Australia AU2018202956 2034-01-24 ⤷  Sign Up
RIST4721 Australia AU2019202675 2034-01-24 ⤷  Sign Up
RIST4721 Canada CA2935625 2034-01-24 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.